Details for Patent: 11,331,292
✉ Email this page to a colleague
Which drugs does patent 11,331,292 protect, and when does it expire?
Patent 11,331,292 protects IQIRVO and is included in one NDA.
This patent has twenty-one patent family members in fourteen countries.
Recent additions to Drugs Protected by US Patent 11,331,292
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | IQIRVO | elafibranor | TABLET | 218860 | Jun 10, 2024 | RX | Yes | ⤷ Subscribe | ⤷ Subscribe | U-1854 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,331,292
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,331,292
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2017242819 | ⤷ Subscribe | |||
Brazil | 112018069023 | ⤷ Subscribe | |||
Canada | 3018132 | ⤷ Subscribe | |||
China | 109152756 | ⤷ Subscribe | |||
China | 114796237 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |